Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540050 | 0.83 | KDM4E (0.48) | KMT2AMEN1 | |
| SCHEMBL7193865 | 0.83 | KDM4E (0.48) | KMT2AMEN1 | |
| SCHEMBL7193869 | 0.83 | KDM4E (0.48) | KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6540861 | 0.82 | TACR1 (0.39) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6541358 | 0.81 | PLA2G1B (0.36) | KMT2AMEN1POLBMAPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6541618 | 0.80 | MAPT (0.48) | KMT2AMEN1POLBL3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL6541378 | 0.80 | TACR1 (0.47) | ALDH1A1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6541085 | 0.80 | KDM4E (0.51) | KMT2AMEN1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL6540636 | 0.79 | MEN1 (0.43) | KMT2AMEN1SLC6A2SLC6A4 | |
| SCHEMBL7199745 | 0.79 | MEN1 (0.43) | KMT2AMEN1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | KMT2A 2124/4885MEN1 629/4885POLB 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.